In silico molecular docking of astaxanthin and sorafenib with different apoptotic proteins involved in hepatocellular carcinoma

Suganya, V.; Anuradha, V.

doi:10.1016/j.bcab.2019.101076

Cited by 17 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the lowest dose of astaxanthin (20 μM) inhibited cell growth with the same efficacy of cisplatin, a conventional anticancer drug, used as control [47]. By in silico molecular docking, Suganya and Anuradha [48] demonstrated that astaxanthin can reach higher scores compared with that obtained with a standard chemotherapic agent, sorafenib, in hepatocellular carcinoma. Previous results report time-(24 − 72 h) and dose-dependent (4 − 16 μM) antiproliferative properties of astaxanthin against HCT116 and HT-29 [49], as well as of the entire H. pluvialis extract (5-25 μg/mL).…”

Section: Astaxanthin Pharmacological Properties/anti-cancer Effects I...mentioning

confidence: 99%

Astaxanthin anticancer effects are mediated through multiple molecular mechanisms: A systematic review

Faraone

Sinisgalli

Ostuni

et al. 2020

Pharmacological Research

106

View full text Add to dashboard Cite

Section: Astaxanthin Pharmacological Properties/anti-cancer Effects I...mentioning

confidence: 99%

Astaxanthin anticancer effects are mediated through multiple molecular mechanisms: A systematic review

Faraone

Sinisgalli

Ostuni

et al. 2020

Pharmacological Research

106

View full text Add to dashboard Cite

“…This anticancer drug was used as a control [107]. With the help of in silico molecular docking, Suganya and Anuradha [108] reported that in hepatocellular carcinoma, ASX can show a more pronounced effect than the standard chemotherapy agent sorafenib. Hormozi et al [109] studied the LS-180 cell line and observed apoptosis and antioxidant activity; an overall increase in the Bax and Caspase3 gene expression, with a decrease in Bcl2 and the growth cells proliferation inhibition, was observed after supplementing with ASX.…”

Section: Anticancer Activitymentioning

confidence: 99%

Astaxanthin: A super antioxidant from microalgae and its therapeutic potential

Kumar

Diksha

et al. 2021

J Basic Microbiol

View full text Add to dashboard Cite

Astaxanthin is a ketocarotenoid, super antioxidant molecule. It has higher antioxidant activity than a range of carotenoids, thus has applications in cosmetics, aquaculture, nutraceuticals, therapeutics, and pharmaceuticals.Naturally, it is derived from Haematococcus pluvialis via a one-stage process or two-stage process. Natural astaxanthin significantly reduces oxidative and free-radical stress as compared to synthetic astaxanthin. The present review summarizes all the aspects of astaxanthin, including its structure, chemistry, bioavailability, and current production technology. Also, this paper gives a detailed mechanism for the potential role of astaxanthin as nutraceuticals for cardiovascular disease prevention, skin protection, antidiabetic and anticancer, cosmetic ingredient, natural food colorant, and feed supplement in poultry and aquaculture. Astaxanthin is one of the high-valued microalgae products of the future. However, due to some risks involved or not having adequate research in terms of long-term consumption, it is still yet to be explored by food industries. Although the cost of naturally derived astaxanthin is high, it accounts for only a 1% share in total astaxanthin available in the global market. Therefore, scientists are looking for ways to cut down the cost of natural astaxanthin to be made available to consumers.

show abstract

“…Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the two most common histologic forms of the primary liver cancer. HCC comprises about 75% of the liver cancer cases, whereas ICC accounts for only about 12-15% of all the liver cancer cases throughout the world [6][7][8][9]. Hemangiocarcinoma accounts for 1% of all liver cancers, whereas secondary liver cancer or liver metastasis accounts for the rest of the liver cancer cases [10].…”

Section: Introductionmentioning

confidence: 99%

“…There are numerous routes involved in the development of cancer. Blocking one or more components of a specific pathway involved in cancer formation is a common strategy for developing anticancer drugs [9].…”

Section: Introductionmentioning

confidence: 99%

Multitargeted molecular docking study of phytochemicals on hepatocellular carcinoma

Jha¹,

Bhosale²,

Kapadia³

et al. 2022

J App Biol biotech

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fourth major cause of death worldwide, with a global diminishing survival rate of 19%. Irrespective of the advanced therapeutic strategies against this carcinoma, it persists as one of the most challenging diseases. Moreover, the low efficacy of existing treatment stratagem using synthetic drugs against HCC has led to the urgent investigation of natural alternatives that can result in a more efficient treatment with fewer health side effects than their synthetic counterparts. In this study, a total of 1259 phytochemicals were docked against 25 potential HCC protein targets with the help of PyRx, a virtual screening tool software. The pharmacokinetics and drug-like properties of these chemicals were examined through SWISS ADME webserver. Based on their binding affinity against each protein target, only 250 ligands were shortlisted further for toxicity analysis using the web tools ADMETlab 2.0 and Protox II. In accordance with the bioavailability radar and pharmacokinetic profile analysis, only two non-toxic phytochemicals: Sorgolactone and Alectrol, emerged as the most befitting drug candidates against HCC protein targets 6HH1 and 1ZXM, respectively. The findings of this study suggest that these two phytochemicals can be explored and exploited further for their use as potential HCC drug candidates.

show abstract

In silico molecular docking of astaxanthin and sorafenib with different apoptotic proteins involved in hepatocellular carcinoma

Cited by 17 publications

References 19 publications

Astaxanthin anticancer effects are mediated through multiple molecular mechanisms: A systematic review

Astaxanthin anticancer effects are mediated through multiple molecular mechanisms: A systematic review

Astaxanthin: A super antioxidant from microalgae and its therapeutic potential

Multitargeted molecular docking study of phytochemicals on hepatocellular carcinoma

Contact Info

Product

Resources

About